Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Cancer cases in India estimated to reach 1.57 million in 2025
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
Subscribe To Our Newsletter & Stay Updated
